Abstract:Objective To investigate the effect of febuxostat on diabetic nephropathy with hyperuricemia and its improvement on renal function.Methods From January 2021 to October 2022, 83 cases of diabetic nephropathy with hyperuricemia in Fangcheng County People's Hospital were selected. According to the random number table method, they were divided into two groups, all of whom received routine treatment of diabetes. One group of 41 cases treated with allopurinol tablets was selected as the control group, and the another group of 42 cases treated with febuxostat was selected as the observation group. Both groups were treated for 3 months and followed up for 6 months. The indexes of the two groups were compared.Results Compared with the control group, the clinical total effective rate of the observation group was higher. Compared with before treatment, the levels of serum uric acid (SUA), urinary albumin excretion rate (UAER), microalbunminuria (MAU), urinary albumin-to-creatinine ratio (ACR), homeostatic model assessment for insulin resistance (HOMA-IR), serum fasting insulin (FINS) and 2-hour postprandial blood glucose (2hPG) of the observation group and the control group decreased after treatment, and the former was even lower. The total incidence of adverse reactions of the observation group was lower than that of the control group during the follow-up period (all P<0.05).Conclusion Febuxostat can improve the therapeutic effect of diabetic nephropathy with hyperuricemia, reduce the level of serum uric acid, improve the level of blood sugar and renal function, and reduce adverse reactions.